Risk of hepatotoxicity associated with fluoroquinolones: A national case-control safety study

American Journal of Health-System Pharmacy

Volumn 71, Issue 1, 2014, Pages 37-43

  Alshammari, Thamir M ^a   Larrat, E Paul ^b   Morrill, Haley J ^c,d   Caffrey, Aisling R ^c,e   Quilliam, Brian J ^d   LaPlante, Kerry L ^d,f,g,h  

^a UNIVERSITY OF HAIL   (Saudi Arabia)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Department of Health   (United States)

^e Department of Pharmacy Practice   (United States)

^f Infectious Diseases Research Program   (United States)

^g Providence VAMC   (United States)

^h BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; VETERAN; AGED; ALCOHOLISM; CASE CONTROL STUDY; FACTUAL DATABASE; GOVERNMENT; MIDDLE AGED; PATIENT SAFETY; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; RISK FACTOR; SOCIOECONOMICS; STATISTICAL ANALYSIS; TOXIC HEPATITIS; UNITED STATES;

ADULT; AGED; ALCOHOLISM; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CASE-CONTROL STUDIES; CIPROFLOXACIN; COMORBIDITY; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; FEMALE; FLUOROQUINOLONES; HOSPITALS, VETERANS; HUMANS; LEVOFLOXACIN; MALE; MIDDLE AGED; PATIENT SAFETY; QUINOLINES; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84906136085     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130165     Document Type: Article

References (54)

1. LaPlante KL, Mersfelder TL, Ward KE et al. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. Pharmacotherapy. 2008; 28:82-9.
2. LaPlante KL, Rybak MJ, Tsuji B et al. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother. 2007; 51:1315-20.
3. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005; 41(suppl 2):S144-57.
4. Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 2011; 66:1431-46.
5. Food and Drug Administration. Trovan information. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/PublicHealthAdvisories/ucm052276.htm (accessed 2012 Sep 9).
6. Coban S, Ceydilek B, Ekiz F et al. Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection. Ann Pharmacother. 2005; 39:1737-40.
7. Zimpfer A, Propst A, Mikuz G et al. Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch. 2004; 444:87-9.
8. Verma R, Dhamija R, Batts DH et al. Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: a case report. Cases J. 2009; 2:8063.
9. Orman ES, Conjeevaram HS, Vuppalanchi R et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011; 9:517-23,e3.
10. Licata A, Randazzo C, Morreale I et al. Fluoroquinolone-induced liver injury: three new cases and a review of the literature. Eur J Clin Pharmacol. 2012; 68:525-32.
11. Hautekeete ML, Kockx MM, Naegels S et al. Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol. 1995; 23:759-60.
12. Schwalm JD, Lee CH. Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient. CMAJ. 2003; 168:847-8.
13. Contreras MA, Luna R, Mulero J et al. Severe ciprofloxacin-induced acute hepatitis. Eur J Clin Microbiol Infect Dis. 2001; 20:434-5.
14. Soto S, Lopez-Roses L, Avila S et al. Moxifloxacin-induced acute liver injury. Am J Gastroenterol. 2002; 97:1853-4.
15. Grassmick BK, Lehr VT, Sundareson AS. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother. 1992; 26:636-9.
16. Fuchs S, Simon Z, Brezis M. Fatal hepatic failure associated with ciprofloxacin. Lancet. 1994; 343:738-9.
17. Spahr L, Rubbia-Brandt L, Marinescu O et al. Acute fatal hepatitis related to levofloxacin. J Hepatol. 2001; 35:308-9.
18. Paterson JM, Mamdani MM, Manno M et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012; 184:1565-70.
19. National Center for Veterans Analysis and Statistics, Department of Veterans Affairs. Quick facts. www.va.gov/vetdata/ (accessed 2013 Jun 2).
20. Caffrey AR, LaPlante KL. Changing epidemiology of methicillin-resistant Staphylococcus aureus in the Veterans Affairs Healthcare System, 2002-2009. Infection. 2012; 40:291-7.
21. Caffrey AR, Quilliam BJ, LaPlante KL. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54:4394-400.
22. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007; 32:483-7.
23. Traversa G, Bianchi C, Da Cas R et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003; 327:18-22.
24. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: John Wiley; 2000.
25. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis. 1994; 18:946-50.
26. Sun Q, Zhu R, Foss FW Jr et al. In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity. Chem Res Toxicol. 2008; 21:711-9.
27. Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med. 2000; 342:359-60.
28. Kramer JR, Davila JA, Miller ED et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008; 27:274-82.
29. Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr Med Res Opin. 2007; 23:1403-13.
30. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 2009; 32:359-78.
31. De Valle MB, Av Klinteberg V, Alem N et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006; 24:1187-95.
32. Bernal W, Auzinger G, Dhawan A et al. Acute liver failure. Lancet. 2010; 376:190-201.
33. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010; 138:2246-59.
34. Dreifuss FE, Santilli N, Langer DH et al. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987; 37:379-85.
35. Heubi JE, Partin JC, Partin JS et al. Reye's syndrome: current concepts. Hepatology. 1987; 7:155-64.
36. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009; 29:337-47.
37. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006; 354:731-9.
38. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol. 1997; 26(suppl 2):12-21.
39. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003; 348:538-49.
40. Lozano-Lanagran M, Robles M, Lucena MI et al. Hepatotoxicity in 2011 - advancing resolutely. Rev Esp Enferm Dig. 2011; 103:472-9.
41. Andrade RJ, Camargo R, Lucena MI et al. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf. 2004; 3:329-44.
42. Pessione F, Ramond MJ, Njapoum C et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology. 2001; 34:121-5.
43. Brown SJ, Desmond PV. Hepatotoxicity of antimicrobial agents. Semin Liver Dis. 2002; 22:157-67.
44. Tolman KG. The liver and lovastatin. Am J Cardiol. 2002; 89:1374-80.
45. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006; 97(8A):77C-81C.
46. Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. Ann Pharmacother. 2010; 44:1655-9.
47. Romero-Gomez M, Otero MA, Suarez-Garcia E et al. Acute hepatitis related to omeprazole. Am J Gastroenterol. 1999; 94:1119-20.
48. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 2001; 21(suppl 10, pt 2):253S-272S.
49. Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. J Hepatol. 2002; 37:696-9.
50. Petersen LA, Wright S, Normand SL et al. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med. 1999; 14:555-8.
51. Schneeweiss S, Robicsek A, Scranton R et al. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007; 60:397-409.
52. Abraham NS, Cohen DC, Rivers B et al. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal antiinflammatory drug prescription. Aliment Pharmacol Ther. 2006; 24:299-306.
53. Myers RP, Leung Y, Shaheen AA et al. Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data. BMC Health Serv Res. 2007; 7:159.
54. Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007; 102:2437-43.